Prospective Analysis on Survival Outcomes of Nonsmall Cell Lung Cancer Stages over IIIb Treated with HangAm-Dan

Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease. Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation, but results are not satisfactory. Oriental medicine herbal formula, HangAm-Dan (HAD) has...

Full description

Saved in:
Bibliographic Details
Published inZhongguo fei ai za zhi Vol. 13; no. 11; pp. 1009 - 1015
Main Authors Tae-Young, JEONG, PARK, Bong-Ky, LEE, Yeon-Weol, Chong-Kwan, CHO, Hwa-Seung YOO
Format Journal Article
LanguageChinese
Published Tianjin Chinese Anti-Cancer Association Chinese Antituberculosis Association 01.11.2010
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Subjects
Cancer
Cancer therapies
Chemotherapy
HangAm-Dan
Herb
Lung cancer
Lung neoplasms
Medical prognosis
Mortality
Oriental medicine
Overall survival rate
Patients
Online AccessGet full text

Cover

More Information
Summary:Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease. Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation, but results are not satisfactory. Oriental medicine herbal formula, HangAm-Dan (HAD) has been developed for anti-tumor purpose and several previous studies have already reported its effects. The aim of this study is to assess HAD's efficacy on prolonging the survival rate of NSCLC stages over IIIb. Methods We have administered 3 000 mg of HAD daily to patients. The study included 74 first visit patients of East-West Cancer Center (EWCC) from November 2007 to April 2008, diagnosed with inoperable NSCLC stages over IIIb. Among them, 30 patients were in HAD group and 44 patients were in combined group with conventional therapy and HAD. We have observed and analyzed their overall survival. Results Of total 74 patients, overall 1 year, 2 year survival rates and the median survival time were 62.1%, 34.9% an
ISSN:1009-3419
1999-6187
DOI:10.3779/cjlc.v13i11.1865